Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription


1 AJR Am J Roentgenol
1 BJU Int
1 BMC Cancer
3 BMC Urol
1 Endocrinology
6 Eur Urol
2 Int J Cancer
1 Int J Oncol
1 Int J Radiat Oncol Biol Phys
1 Int J Urol
1 Invest Radiol
1 J Nucl Med
1 Magn Reson Med
2 Oncogene
1 Oncol Rep
1 PLoS One
6 Prog Urol
2 Prostate
1 Radiol Imaging Cancer
1 Urol Int

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. ABREU-GOMEZ J, Dias AB, Ghai S
    PI-RR: The Prostate Imaging for Recurrence Reporting System for MRI Assessment of Local Prostate Cancer Recurrence After Radiation Therapy or Radical Prostatectomy-A Review.
    AJR Am J Roentgenol. 2023 Feb 1. doi: 10.2214/AJR.22.28665.
    PubMed         Abstract available

    BJU Int

    Do not treat Bill Gates for prostate cancer! Algorithmic bias and causality in medical prediction.
    BJU Int. 2023 Jan 30. doi: 10.1111/bju.15951.

    BMC Cancer

  3. CHENG X, Zeng Z, Yang H, Chen Y, et al
    Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    BMC Cancer. 2023;23:105.
    PubMed         Abstract available

    BMC Urol

  4. XIONG T, Jiang M, Ye X, Zhu G, et al
    Skull metastasis is a poor prognostic factor for prostate cancer patients with bone metastasis: a retrospective study based on a Chinese population.
    BMC Urol. 2023;23:13.
    PubMed         Abstract available

  5. YANG L, Li S, Liu X, Liu J, et al
    A nomogram model for determining optimal patients for local therapy in metastatic prostate cancer: a SEER database-based study.
    BMC Urol. 2023;23:12.
    PubMed         Abstract available

  6. LU M, Luo Y, Wang Y, Yu J, et al
    Transrectal versus transperineal prostate biopsy in detection of prostate cancer: a retrospective study based on 452 patients.
    BMC Urol. 2023;23:11.
    PubMed         Abstract available


  7. NOURUZI S, Tabrizian N, Zoubeidi A
    Beyond expression: role of phosphorylated residues of EZH2 in lineage plasticity in prostate cancer.
    Endocrinology. 2023 Jan 30:bqad023. doi: 10.1210.
    PubMed         Abstract available

    Eur Urol

    Re: Prostate Cancer Polygenic Risk Score and Prediction of Lethal Prostate Cancer.
    Eur Urol. 2023 Jan 27:S0302-2838(23)00013-1. doi: 10.1016/j.eururo.2023.

  9. MELL LK, Pugh SL, Jones CU, Nelson TJ, et al
    Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.
    Eur Urol. 2023 Jan 27:S0302-2838(23)00056-8. doi: 10.1016/j.eururo.2023.
    PubMed         Abstract available

  10. COMPERAT E, Oszwald A, Wasinger G
    Re: Percentage Gleason Pattern 4 and PI-RADS Score Predict Upgrading in Biopsy Grade Group 2 Prostate Cancer Patients Without Cribriform Pattern.
    Eur Urol. 2023 Jan 25:S0302-2838(23)00015-5. doi: 10.1016/j.eururo.2023.

  11. BORGHESI M, Bauckneht M, Terrone C
    Re: Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography.
    Eur Urol. 2023;83:185-186.

  12. POWELL K, Burns MC, Prasad V
    Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint.
    Eur Urol. 2023;83:101-102.
    PubMed         Abstract available

  13. STUDENT V JR, Tudos Z, Studentova Z, Cesak O, et al
    Effect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial.
    Eur Urol. 2023;83:154-162.
    PubMed         Abstract available

    Int J Cancer

  14. LILLEBY W, Seierstad T, Inderberg EM, Hole KH, et al
    Impact of hTERT peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring.
    Int J Cancer. 2023 Jan 30. doi: 10.1002/ijc.34448.
    PubMed         Abstract available

  15. KLUSA D, Lohaus F, Franken A, Baumbach M, et al
    Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy.
    Int J Cancer. 2023 Feb 2. doi: 10.1002/ijc.34457.
    PubMed         Abstract available

    Int J Oncol

  16. SHI SJ, Han DH, Zhang JL, Li Y, et al
    VIM‑AS1 promotes proliferation and drives enzalutamide resistance in prostate cancer via IGF2BP2‑mediated HMGCS1 mRNA stabilization.
    Int J Oncol. 2023;62:34.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  17. SUTERA P, Deek MP, Van der Eecken K, Shetty AC, et al
    WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer.
    Int J Radiat Oncol Biol Phys. 2023 Jan 25:S0360-3016(22)03628.
    PubMed         Abstract available

    Int J Urol

  18. KITAMURA K, China T, Nagata M, Isotani S, et al
    Prediction of recovery time of urinary incontinence following robot-assisted laparoscopic prostatectomy.
    Int J Urol. 2023;30:77-82.
    PubMed         Abstract available

    Invest Radiol

  19. AL-BOURINI O, Seif Amir Hosseini A, Giganti F, Balz J, et al
    T1 Mapping of the Prostate Using Single-Shot T1FLASH: A Clinical Feasibility Study to Optimize Prostate Cancer Assessment.
    Invest Radiol. 2022 Dec 8. doi: 10.1097/RLI.0000000000000945.
    PubMed         Abstract available

    J Nucl Med

  20. TRAPP C, Oliinyk D, Rogowski P, Von Bestenbostel R, et al
    An analysis of PSMA-PET/CT-positive lymph node distribution and their coverage by different elective nodal radiation volumes in postoperative prostate cancer patients.
    J Nucl Med. 2023 Feb 2:jnumed.122.265159. doi: 10.2967/jnumed.122.265159.
    PubMed         Abstract available

    Magn Reson Med

  21. XU Z, Michel KA, Walker CM, Harlan CJ, et al
    Model-constrained reconstruction accelerated with Fourier-based undersampling for hyperpolarized [1-(13) C] pyruvate imaging.
    Magn Reson Med. 2023;89:1481-1495.
    PubMed         Abstract available


  22. ZHOU J, Wang Y, Wu D, Wang S, et al
    Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer.
    Oncogene. 2021;40:2625-2634.
    PubMed         Abstract available

  23. SCOTT E, Hodgson K, Calle B, Turner H, et al
    Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.
    Oncogene. 2023 Feb 1. doi: 10.1038/s41388-023-02604.
    PubMed         Abstract available

    Oncol Rep

  24. KOU B, Liu W, Zhao W, Duan P, et al
    [Corrigendum] Thymoquinone inhibits epithelial‑mesenchymal transition in prostate cancer cells by negatively regulating the TGF‑beta/Smad2/3 signaling pathway.
    Oncol Rep. 2023;49:54.
    PubMed         Abstract available

    PLoS One

  25. HAN JH, Chung DH, Cho MC, Ku JH, et al
    Natural history of incidentally diagnosed prostate cancer after holmium laser enucleation of the prostate.
    PLoS One. 2023;18:e0278931.
    PubMed         Abstract available

    Prog Urol

  26. LASSERRE M, Sargos P, Barret E, Beauval JB, et al
    Narrative review of PET/CT performances at biochemical recurrence in prostate cancer after radical prostatectomy and impact on patient disease management: Revue narrative a propos des performances de la TEP/TDM en cas de recidive biochimique apres pro
    Prog Urol. 2022;32.
    PubMed         Abstract available

  27. DIAMAND R, Mjaess G, Ploussard G, Fiard G, et al
    Magnetic Resonance Imaging-Targeted Biopsy and Pretherapeutic Prostate Cancer Risk Assessment: a Systematic Review: Biopsie ciblee par Imagerie par resonance magnetique et evaluation pre-therapeutique du risque de cancer de la prostate : revue systema
    Prog Urol. 2022;32.
    PubMed         Abstract available

  28. MARTEL P, Rakauskas A, Dagher J, La Rosa S, et al
    The benefit of adopting Microultrasound in the prostate cancer imaging pathway: A lesion-by-lesion analysis: Biopsies prostatiques guidee par micro-echographie, quel benefice ? Une analyse lesion par lesion.
    Prog Urol. 2022;32.
    PubMed         Abstract available

  29. FIARD G, Giganti F
    How MRI is changing prostate cancer management: a focus on early detection and active surveillance: Comment l'IRM est en train de revolutionner la prise en charge du cancer de la prostate : focus sur la detection precoce et la surveillance active.
    Prog Urol. 2022;32.
    PubMed         Abstract available

  30. KLEINCLAUSS F, Ploussard G
    How imaging is changing prostate cancer management - Editorial: Comment l'imagerie peut revolutionner le traitement du cancer de la prostate - Editorial.
    Prog Urol. 2022;32.

  31. BABOUDJIAN M, Gauthe M, Barret E, Brureau L, et al
    How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Metastatique Resistant a la Castration ?
    Prog Urol. 2022;32.
    PubMed         Abstract available


  32. BRAY G, Bahadori A, Rama D
    Salvage stereotactic body radiation therapy for locally recurrent prostate cancer following primary radiation therapy, are benefits worth toxicity risks?: A systematic review.
    Prostate. 2023 Jan 30. doi: 10.1002/pros.24491.
    PubMed         Abstract available

  33. RAM P, Mandal S, K Das M, Nayak P, et al
    The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    Prostate. 2023 Jan 30. doi: 10.1002/pros.24489.

    Radiol Imaging Cancer

    Next-Generation Diffusion Imaging of Osseous Metastases.
    Radiol Imaging Cancer. 2023;5:e220167.

    Urol Int

  35. LOPCI E, Lazzeri M, Colombo P, Casale P, et al
    Diagnostic Performance and Clinical Impact of PSMA PET/CT versus mpMRI in Patients with a High Suspicion of Prostate Cancer and Previously Negative Biopsy: A Prospective Trial (PROSPET-BX).
    Urol Int. 2023 Feb 1:1-7. doi: 10.1159/000528720.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.